KARO BIO'S NOMINATING COMMITTEE FOR THE ANNUAL GENERAL MEETING 2010 APPOINTED

KARO BIO'S NOMINATING COMMITTEE FOR THE ANNUAL GENERAL MEETING 2010 APPOINTED

STOCKHOLM, SWEDEN, November 10, 2009. Karo Bio (Reuters: KARO.ST) today
announced that a nominating committee for the Annual General Meeting 2010 has
been appointed.

In accordance with principles for appointment of a nominating committee resolved
by the Annual General Meeting 2009, the following persons, together with the
chairman of the board Leon E. Rosenberg, have been appointed to be members of
the nominating committee for the Annual General Meeting 2010: Bengt Belfrage
(Nordea), Ragnhild Wiborg (Concepio), Thomas Josefsson (Borås Postorder) and
Johan Claesson (CA Fastigheter).  Shareholders can submit proposals to the
nominating committee at the following address: Nominating Committee, Karo Bio
AB, Novum, S-141 57 Huddinge, Sweden. The nominating committee's proposal will
be published at the latest in connection with the notice for the Annual General
Meeting. The term of office of the nominating committee runs until a new
nominating committee has been appointed in accordance with the resolution on
appointment of the nominating committee by the Annual General Meeting 2010. 

For more information please contact:
Per Olof Wallström, President
Tel: +46 8 608 60 20
E-mail: p.o.wallstrom@karobio.se

Erika Söderberg Johnson, CFO and responsible for Investor Relations
Tel: +46 8 608 60 52
E-mail: erika.soderberg.johnson@karobio.se

About Karo Bio
Karo Bio is a drug discovery and development company specializing in
endocrinology and targeting nuclear receptors as target proteins for the
development of novel pharmaceuticals. The company has a project portfolio with
innovative molecules that primarily target dyslipidemia, CNS-disorders,
inflammation, and women's health. In these areas, there are significant market
opportunities and a clear need for pharmaceuticals with new mechanisms of
action. Karo Bio develops compounds aimed at treating broad patient populations
up to clinical proof of concept before out-licensing. In therapeutic niche
areas, Karo Bio has the capacity to bring selected compounds into late stage
clinical development and, potentially, to the market. In addition to the
proprietary projects, Karo Bio has three strategic collaborations with
international pharmaceutical companies for development of innovative therapies
for the treatment of common diseases. Karo Bio is listed on NASDAQ OMX Stockholm
since 1998 (Reuters: KARO.ST).


This press release is also available online at: www.karobio.com and
www.newsroom.cision.com